JMP Securities Lowers Werewolf Therapeutics (NASDAQ:HOWL) Price Target to $4.00

Werewolf Therapeutics (NASDAQ:HOWL) had its price objective lowered by equities research analysts at JMP Securities from $12.00 to $4.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm presently has a “market outperform” rating on the stock. JMP Securities’ target price would suggest a potential upside of 187.77% from the company’s previous close.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Werewolf Therapeutics in a report on Tuesday, November 19th.

Werewolf Therapeutics Price Performance

Shares of NASDAQ:HOWL opened at $1.39 on Tuesday. The company has a market capitalization of $61.94 million, a PE ratio of -0.91 and a beta of 0.38. The business has a fifty day moving average price of $1.75 and a 200-day moving average price of $2.10. Werewolf Therapeutics has a 1-year low of $1.31 and a 1-year high of $8.19. The company has a debt-to-equity ratio of 0.29, a current ratio of 10.10 and a quick ratio of 10.10.

Institutional Investors Weigh In On Werewolf Therapeutics

Several institutional investors have recently modified their holdings of the business. Millennium Management LLC lifted its stake in Werewolf Therapeutics by 96.4% during the 2nd quarter. Millennium Management LLC now owns 1,110,298 shares of the company’s stock valued at $2,709,000 after acquiring an additional 544,881 shares during the period. Geode Capital Management LLC lifted its position in Werewolf Therapeutics by 6.3% during the third quarter. Geode Capital Management LLC now owns 685,989 shares of the company’s stock valued at $1,454,000 after purchasing an additional 40,692 shares during the period. Barclays PLC boosted its holdings in Werewolf Therapeutics by 130.1% in the third quarter. Barclays PLC now owns 54,810 shares of the company’s stock worth $116,000 after purchasing an additional 30,990 shares during the last quarter. State Street Corp grew its position in Werewolf Therapeutics by 12.4% in the 3rd quarter. State Street Corp now owns 476,439 shares of the company’s stock worth $1,010,000 after purchasing an additional 52,528 shares during the period. Finally, Renaissance Technologies LLC lifted its holdings in shares of Werewolf Therapeutics by 103.1% during the 2nd quarter. Renaissance Technologies LLC now owns 171,000 shares of the company’s stock valued at $417,000 after buying an additional 86,800 shares during the period. 64.84% of the stock is owned by hedge funds and other institutional investors.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.